P=N/A, N=100, Recruiting, Nanjing University School of Medicine

P4, N=267, Recruiting, Reade Rheumatology Research Institute | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=30, Recruiting, St. Joseph's Hospital and Medical Center, Phoenix | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2023 --> Sep 2024

P3, N=2, Completed, Seoul National University Hospital | Unknown status --> Completed | N=30 --> 2

P=N/A, N=600, Recruiting, Fresenius Kabi, France | Trial completion date: Nov 2024 --> Sep 2025 | Trial primary completion date: Nov 2023 --> Sep 2025

P4, N=220, Not yet recruiting, Centre Hospitalier Universitaire de Saint Etienne | Trial primary completion date: Dec 2026 --> Jan 2026

P2, N=50, Recruiting, Rutgers, The State University of New Jersey | Trial completion date: Jul 2024 --> Jun 2026 | Trial primary completion date: Jan 2024 --> Jan 2026

P2, N=53, Completed, Celgene | Trial primary completion date: Nov 2018 --> Sep 2023

P2/3, N=230, Recruiting, MediciNova | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

The PBMCs of patients with HS were co-cultured with naïve MSCs (n-MSCs), activated with tumor necrosis factor (TNF)-α (10 ng/mL) and interferon (IFN)-γ (10 ng/mL) MSCs (a-MSCs), or adalimumab (30 μg/mL)...Moreover, the preactivation of MSCs with IFN-γ and TNF-α before use can enhance their therapeutic effectiveness. Nevertheless, a larger sample size is imperative to validate these results.

P4, N=30, Recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Not yet recruiting --> Recruiting

P2, N=48, Completed, IRCCS San Raffaele | Unknown status --> Completed

P=N/A, N=38, Completed, Qianfoshan Hospital | Recruiting --> Completed | N=60 --> 38 | Trial completion date: May 2024 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023

In this study we investigated the CNS behaviors and expression/function of BBB OAT3 in AKI rats and mice, which received intraperitoneal injection of cisplatin 8 and 20 mg/kg, respectively...The alterations caused by TNFα and CMs in vitro, and by AKI and TNFα in vivo were abolished by infliximab, a monoclonal antibody designed to intercept and neutralize TNFα, suggesting that AKI impaired the expressions of OAT3, synaptophysin and MAP2 in the brain via IS-induced TNFα release from macrophages or microglia (termed as IS-TNFα axis)...We conclude that AKI inhibits the expressions of OAT3, synaptophysin and MAP2 due to IS-induced TNFα release from macrophages or microglia. TNFα impairs the expressions of OAT3, synaptophysin and MAP2 partly via activating NF-κB pathway and inhibiting Nrf2-HO-1 pathway.

Complete remission was maintained for over one year with lenalidomide maintenance therapy. A solitary IgH::MYC chromosomal translocation is extremely rare in multiple myeloma and may be associated with high tumor proliferative capacity, multiple extramedullary lesions, and poor prognosis. Combined therapeutic modalities with novel and conventional chemotherapy and radiation might be a promising treatment strategy for patients with this type of multiple myeloma.

P2, N=98, Recruiting, Philogen S.p.A. | Trial primary completion date: Dec 2023 --> Dec 2024

P1, N=0, Withdrawn, Philogen S.p.A. | N=24 --> 0 | Not yet recruiting --> Withdrawn

P3, N=102, Recruiting, Philogen S.p.A. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025

P1, N=2, Active, not recruiting, Philogen S.p.A. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P3, N=193, Completed, UCB BIOSCIENCES GmbH | Active, not recruiting --> Completed

P1/2, N=142, Recruiting, Philogen S.p.A. | Trial primary completion date: Nov 2023 --> Mar 2025

These results suggest that the secretome derived from ASCs that synthesize etanercept has potential as a therapeutic agent for the treatment of IBD, potentially enhancing treatment efficacy by merging the anti-inflammatory qualities of the ASC secretome with etanercept's targeted approach to better address the multifaceted pathophysiology of IBD.

P3, N=226, Active, not recruiting, National Cancer Institute (NCI)

P3, N=525, Active, not recruiting, National Cancer Institute (NCI)

The results clearly indicate that sinomenine demonstrated a protective effect against DSS-induced inflammation, potentially through the modulation of inflammatory pathways and gut microbiota.

However, the effect of the applied treatment on the concentration of some cytokines was found: a negative association of infliximab, vedolizumab, and prednisone with IL-2, a positive correlation of steroids, thiopurines with IL-10, and in the case of tumor necrosis factor-α (TNF-α), negative with infliximab, and positive with vedolizumab. The increased concentration of IL-2 may result from its regulatory role in inhibiting excessive activation of the immune system; however, considering the studies of patients with severe COVID-19, its role in the initial phase of SARS-CoV-2 infection requires further research.

P2, N=94, Enrolling by invitation, Xentria, Inc. | Not yet recruiting --> Enrolling by invitation

P2, N=66, Not yet recruiting, ReAlta Life Sciences, Inc.

In conclusion, innate and adaptive immune cell type composition at baseline may be a major contributor to response to adalimumab in axSpA patients. A model including clinical and gene expression variables should also be considered.

A bispecific nanobody (BsNb) was created to target TNF-α and IL-23p19, exhibiting high affinity and remarkable stability. BsNb-Fc inhibited the release of cytokines in CD4+T cells during co-culture experiments. BsNb-Fc effectively alleviated colitis severity in mouse model with acute colitis induced by DSS or TNBS, outperforming the IFX&UST combination.

The improvement of the therapeutic potential by AMFA engineering was investigated using two antibodies directed against soluble antigens: infliximab (IFX), directed against tumor necrosis factor α (TNF-α), and bevacizumab (BVZ), directed against the vascular endothelial growth factor (VEGF). These results demonstrate that AMFA grafting induces the degradation of soluble antigens and a significant increase in the therapeutic efficacy. Engineering with mannose 6-phosphate analogues has the potential to develop a new class of antibodies for autoimmune and inflammatory diseases.

P1, N=18, Recruiting, Sorriso Pharmaceuticals, Inc. | N=42 --> 18

In conclusion, cinnamon acted synergistically with infliximab to mitigate inflammation when used as an extract. Purified bioactive TCA also showed synergistic activity. Thus, aCE, or cinnamon bioactive may be used as a CAM to improve patients' quality of life.

Moreover, a blockade of TNFR signaling through its ligand lymphotoxin-α (LTA), overexpressed in airway epithelial cells under oxidative stress conditions, using the anti-tumor necrosis factor (TNF) biologic etanercept significantly increased the viability of these cells from a toxic oxidizing agent. Furthermore, bioinformatic analyses considering our previous RNA interference (RNAi) screening output highlight the relevance of TNFRSF1B and of other genes within the TNF pathway leading to epithelial cell death. Thus, the inhibition of the LTα3-TNFR2 axis could represent a useful therapeutic strategy to protect the respiratory airway epithelial lining from the oxidative stress challenge because of recurrent infection/inflammation cycles faced by CF patients.

P2, N=90, Not yet recruiting, Philogen S.p.A.

P=N/A, N=18, Not yet recruiting, Tufts Medical Center | Trial completion date: Jan 2025 --> May 2025 | Initiation date: Jan 2024 --> May 2024 | Trial primary completion date: Jan 2025 --> May 2025

P2, N=715, Recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2030 --> Mar 2029

P2, N=550, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2030 --> Mar 2029

P2, N=1, Terminated, ECOG-ACRIN Cancer Research Group | Trial completion date: Jul 2025 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Dec 2023; Slow accrual

Super-responders treated with adalimumab have a higher rate of being female and fewer comorbidities. And super-responders have better PASI responses than non-super-responders, whether the patients were treated with adalimumab or switched to IL-17A inhibitors.

Notably, subtypes A and B presented good responses to methotrexate and interleukin-12/23 inhibitors (ustekinumab) but inadequate responses to tumor necrosis factor-α inhibitors and interleukin-17A receptor inhibitors. Contrastly, subtype C exhibited excellent responses to tumor necrosis factor-α inhibitors (etanercept) and interleukin-17A receptor inhibitors (brodalumab) but not methotrexate and interleukin-12/23 inhibitors. Psoriasis patients can be assorted into three subtypes with different molecular and cellular characteristics based on the heterogeneity of the skin's immune cells and the stroma, determining the clinical responses of conventional therapies.

P2, N=36, Recruiting, Massachusetts General Hospital | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2023 --> Jun 2025